Effects of naringin on reversing cisplatin resistance and the Wnt/β-catenin pathway in human ovarian cancer SKOV3/CDDP cells

Abstract

Objective Ovarian cancer is one of three malignant tumors of the female reproductive system. Our previous studies showed that the traditional Chinese medicine naringin significantly inhibited the proliferation of platinum-resistant ovarian cancer cells in vitro, and that the mechanism may be related to the NF-κB pathway. Methods The MTT assay was used to detect the sensitivity of SKOV3 and SKOV3/CDDP cells to cisplatin, the effect of different naringin concentrations on the proliferation of SKOV3/CDDP cells, and the reversal of cisplatin resistance in naringin-treated SKOV3/CDDP cells. Western blotting was used to detect β-catenin, c-Myc, and cyclin D1 protein levels in the different cell lines. Results MTT results showed that different concentrations of naringin inhibited the proliferation of SKOV3 and SKOV3/CDDP cells, and that the inhibition increased with increasing concentrations and prolonged incubation times. Western blotting revealed that compared with controls (SKOV3/CDDP-0), β-catenin, c-Myc and cyclin D1 proteins levels were significantly decreased in SKOV3/CDDP-C, SKOV3/CDDP-N 20, and SKOV3/CDDP-CN 20 cells, suggesting that naringin inhibited the proliferation of SKOV3/CDDP cells in a concentration and time dependent manner. Conclusions Non-cytotoxic naringin reduced the expression of β-catenin, c-Myc, and cyclin D1 in SKOV3/CDDP cells and partially reversed cisplatin resistance in SKOV3/CDDP CN 20 cells.

Plant-Derived Chinese Medicine Monomers on Ovarian Cancer via the Wnt/β-Catenin Signaling Pathway: Review of Mechanisms and Prospects

“…Epigallocatechin-3-gallate (EGCG) is extracted from green tea and has been shown to have multiple effects on both pathological and physiological processes in humans [87]. In recent years, a large number of Naringin β-Catenin, cyclin D1, c-Myc Inhibiting proliferation, invasion, and migration; reversing transformation therapy resistance [68] studies have confirmed that EGCG has a strong pharmacological effect on the prevention and treatment of tumors [88]. Long and Tang [62] studied the effects of EGCG on the proliferation of HO8910 OC cells and Wnt/β-catenin signaling pathway-related gene expression in the cells.…”

“…The mechanism of this activity may be related to the Wnt/ β -catenin signaling pathway. In addition, the combination of naringin with cisplatin might prevent cell cycle progression, thereby inhibiting the proliferation, invasion, and migration of OC cells [ 68 ].…”

Naringenin inhibits autophagy and epithelial‐mesenchymal transition of human lens epithelial cells by regulating the Smad2/3 pathway

“…Through wound healing and Immunoblot assays, we demonstrated the effects of Naringenin on TGF‐β2 induced LEC migration, EMT, and autophagy. It was reported that Naringenin has multiple biological activities, such as antidyslipidemia, and anti‐obesity (Q. Zhu et al, 2020). Naringenin also showed strong anti‐inflammatory and antioxidant activities in body organs via enhancing of glutathione S‐transferase, glutathione peroxidase, and catalase activity (Albayrak et al, 2021).…”

“…It has been reported that NRG has ameliorative effects on a variety of fibrotic diseases by inhibiting the NF‐κB, TGF‐β‐Smad3 and JNK‐Smad3 pathways and improving CCl4‐induced liver inflammation, necrosis, and fibrosis (Elsawy et al, 2020). In addition, TGF‐β1, TGFβR1, p‐Smad2/Smad2, and Smad7 protein expression can be decreased to improve diabetic nephropathy, reduce cardiac hypertrophy, and interstitial fibrosis (Elsawy et al, 2020; Zhu, Zou, Lin, Hu, & Gao, 2020b). NRG also inhibited mycoplasma pneumoniae (MP)‐induced inflammation and pulmonary fibrosis by inhibiting autophagy (Ye et al, 2020).…”

Low expression of MYCN promotes cisplatin resistance by suppressing cisplatin‑induced apoptosis in epithelial ovarian cancer

“…Cells and cell culture. The human EOC SK-OV-3 cell line, which is commonly used in the study of cisplatin-resistant in serous EOC (29,30), was purchased from Jiangsu KeyGEN BioTECH Co., Ltd. The human EOC cisplatin-resistant SK-OV-3/DDP cell line was purchased from Shanghai Chuan Qiu Biotechnology Co., Ltd.…”